A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in <i>Pseudomonas aeruginosa</i>

This study presents a validated two-stage risk assessment model to discriminate the two phases of meropenem heteroresistance in P. aeruginosa. By identifying novel stage-specific risk factors and delivering a practical tool compatible with clinical workflows, this model facilitates the early identification and targeted intervention of HR, offering novel insights into the mechanistic dissection of HR.